Prahlad V. Raninga

Prahlad V. Raninga is a male medical professional who specializes in treating Triple-Negative Breast Cancer, Breast Cancer, and Multiple Myeloma. He helps patients by providing specialized care and treatments for these conditions.

Prahlad V. Raninga is known for his exceptional skills in dealing with complex cases of breast cancer and multiple myeloma. He uses advanced techniques and therapies to help his patients fight these diseases.

Patients trust Prahlad V. Raninga because he communicates with them in a caring and understanding way. He listens to their concerns and explains their treatment options clearly, making sure they feel supported throughout their medical journey.

To stay updated with the latest medical knowledge and research, Prahlad V. Raninga regularly attends conferences, reads medical journals, and collaborates with other experts in the field. This helps him provide the most up-to-date and effective treatments to his patients.

Prahlad V. Raninga works closely with his colleagues and other medical professionals to ensure the best outcomes for his patients. He values teamwork and believes in a collaborative approach to patient care, which leads to better results for those under his care.

Through his dedication and expertise, Prahlad V. Raninga has positively impacted many patients' lives and health. His innovative treatments and personalized care have helped improve the outcomes and quality of life for those battling breast cancer and multiple myeloma.

One of Prahlad V. Raninga's notable publications is "Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers," published in Oncogene in March 2025. This research highlights his commitment to advancing treatment options for specific types of breast cancer.

Overall, Prahlad V. Raninga's dedication to his patients, commitment to staying informed, and collaborative approach with colleagues have made him a trusted and respected medical professional in the field of oncology.